Ginkgo Bioworks Q2 Earnings Call Highlights
Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software.
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Core DNA: Coreweave and Nebius Couldn't Be More Different and Why It Matters
CoreWeave (NASDAQ: CRWV) and Nebius Group (NASDAQ: NBIS | NBIS Price Prediction) just delivered Q1 2026 results that look similar on the surface: both are NVIDIA-backed AI cloud providers chasing hyperscaler contracts.
FTAI Aviation: Innovation Is Their DNA
FTAI Aviation is innovatively leveraging jet engine cores to address the urgent power needs of data centers amid an energy bottleneck. FTAI's new power segment, repurposing CFM56 engines, could add 30% to company value by 2027, with significant upside if unit deliveries meet targets. The stock is rated Buy, with a $393 price target (57% upside) based on 25 power units sold in 2027; risk increases as FTAI enters the energy sector.
Ginkgo Bioworks Q1 Earnings Call Highlights
Ginkgo Bioworks NYSE: DNA said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in the first quarter.
TelevisaUnivision Bets Its Telenovela DNA Can Win The Microdrama Race
TelevisaUnivision is moving aggressively to turn its microdrama platform into a new growth engine, betting that the melodramatic storytelling that powered decades of telenovelas can be reshaped for mobile-first audiences in one- to two-minute vertical episodes.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $9, representing a -3.12% change from its previous close.
Amazon's DNA: Why Hoarding Cash Is Secondary To Building Empires
Amazon delivered robust Q4 2025 results, with accelerating revenue growth and AWS leading at 23.6% YoY. AMZN's operating margin reached a historic high of 11.8%, driven by strong AWS profitability at a 35% margin. The stock sold off after management guided FY 2026 CapEx to $200bn, 50% above FY 2025 and exceeding operating cash flow by $60bn.
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.23 at the closing of the latest trading day, reflecting a -9.06% change compared to its last close.
Allegiant Travel: Cost Discipline DNA Returns, Sun Country Airlines' Upside
Allegiant Travel Company demonstrates disciplined capacity management and cost control, supporting a "Buy" rating and strong post-earnings stock performance. Q4 2025 results show a swing to profitability with a 10.2% operating margin, despite modest margin compression and reduced unit revenues. ALGT targets stable capacity and efficiency gains in 2026, leveraging Boeing 737 MAX upgrades to drive cost improvements without diluting unit revenues.
Why Ginkgo Bioworks Holdings, Inc. (DNA) Dipped More Than Broader Market Today
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $8.27, denoting a -5.92% move from the preceding trading day.
